Cost-effectiveness acceptability curve for QALYs. by Lotte Verweij (725951)

Subjects:

Cost-effectiveness plane for QALYs comparing the intervention group to the usual care group. by Lotte Verweij (725951)

Subjects:

Cost-effectiveness plane for estimated readmission or mortality comparing the intervention group with the usual care group. by Lotte Verweij (725951)

Subjects:

Differences in readmission or mortality, QALYs and costs in €, ICERs, distribution of bootstrapped cost-effect pairs over the quadrants of the CE-plane, and the probability of cost... by Lotte Verweij (725951)

Subjects:

Cost-effectiveness acceptability curve for readmission or mortality. by Lotte Verweij (725951)

Subjects:

CCB intervention costs (€). by Lotte Verweij (725951)

Subjects:

Unadjusted mean costs (€) and effects over 6 months follow-up after multiple imputation. by Lotte Verweij (725951)

Subjects:

Baseline characteristics. by Lotte Verweij (725951)

Subjects:

Healthcare costs (€) used in the cost-effectiveness analysis. by Lotte Verweij (725951)

Subjects:

Flowchart. by Lotte Verweij (725951)

Subjects:

Unadjusted primary outcome measures. by Paula Elisabeth van Westrienen (15195132)

Subjects:

Adjusted multivariate comparisons of primary and secondary outcome measures per group based on intention-to-treat analysis at 3 and 12 months. by Paula Elisabeth van Westrienen (15195132)

Subjects:

Overview of the PARASOL intervention. by Paula Elisabeth van Westrienen (15195132)

Subjects:

Characteristics of participants^a. by Paula Elisabeth van Westrienen (15195132)

Subjects:

Flow chart. by Paula Elisabeth van Westrienen (15195132)

Subjects:

Unadjusted effects of retention in care period on treatment standards achievement, exposed (>50% of allowable time), unexposed (< = 50%), N = 211. by John E. Deaver (19470090)

Subjects:

Formation of the cohort of low‐income Peruvians with type 2 diabetes (DM) and/or hypertension (HTN). by John E. Deaver (19470090)

Subjects:

Probabilities of guidelines‐based treatment standards achievement, by program exposure (’post’ versus ’pre’). by John E. Deaver (19470090)

Subjects:

Unadjusted effects of exposures on treatment standards achievement. by John E. Deaver (19470090)

Subjects:

Predicted probabilities of guidelines‐based treatment standards achievement, by retention in care period (>50% versus < = 50% of allowable time for care period). by John E. Deaver (19470090)

Subjects: